Cytokinetics
CYTK
94 hedge funds and large institutions have $133M invested in Cytokinetics in 2015 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 10 closing their positions.
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
37% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 27
11% more funds holding
Funds holding: 85 → 94 (+9)
4% more call options, than puts
Call options by funds: $1.58M | Put options by funds: $1.52M
14% less capital invested
Capital invested by funds: $155M → $133M (-$21.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.13M |
| 2 |
Morgan Stanley
New York
|
+$1.9M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.25M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.08M |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$857K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.95M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.51M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.19M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.51M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$964K |
CYTK Hedge Fund Activity: Q1 2015 in Review
94 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2015, worth a combined $133M — down 14% from $155M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CYTK positions and 10 closed out — a net gain of 9 holders — while 37 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.13M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.95M sold.
- 94 institutional investors held Cytokinetics (CYTK) as of Q1 2015, up from 85 in Q4 2014.
- Funds reported $133M of Cytokinetics stock for Q1 2015, down 14% quarter-over-quarter.
- 19 funds opened new Cytokinetics positions in Q1 2015 and 10 closed out, a net change of +9 holders.
- The largest Cytokinetics buyer in Q1 2015 was Millennium Management, an estimated $2.13M added.
- The largest Cytokinetics seller in Q1 2015 was Sphera Funds Management, an estimated $3.95M sold.
Based on aggregated 13F filings for Q1 2015.